Seres Therapeutics (MCRB) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$21.9 million.
- Seres Therapeutics' Income from Continuing Operations rose 2335.02% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year increase of 1878.51%. This contributed to the annual value of -$117.3 million for FY2024, which is 3832.36% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Income from Continuing Operations is -$21.9 million, which was up 2335.02% from -$24.3 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Income from Continuing Operations peaked at $68.3 million during Q3 2021, and registered a low of -$71.5 million during Q1 2023.
- For the 5-year period, Seres Therapeutics' Income from Continuing Operations averaged around -$28.4 million, with its median value being -$33.4 million (2024).
- Per our database at Business Quant, Seres Therapeutics' Income from Continuing Operations skyrocketed by 32286.69% in 2021 and then crashed by 149549.39% in 2023.
- Seres Therapeutics' Income from Continuing Operations (Quarter) stood at -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 1495.49% to -$35.1 million in 2023, then rose by 18.99% to -$28.4 million in 2024, then increased by 23.03% to -$21.9 million in 2025.
- Its Income from Continuing Operations was -$21.9 million in Q3 2025, compared to -$24.3 million in Q2 2025 and -$26.6 million in Q1 2025.